Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 6 | BMC Cancer

Figure 6

From: Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations

Figure 6

Western-blot analyses of Mcl-1 and Bcl-2 expression levels after sorafenib treatment. (a) Sorafenib treatment led to a marked decrease in the levels of Mcl-1 in the cell line with mutated BRAFV600E (8505C) at all the time points analyzed except after 48 h in 8505C. Mcl-1 levels in TPC1 and C643 cells varied at the different time points after treatment, as shown in the graph (c): in TPC1 cells there was a decrease at all time points; in C643 cells there was a variable response with a increase seen at 1 h and 48 h. (b) Sorafenib induced alterations in the levels of Bcl-2 in the three cell lines. Levels of Bcl-2 protein were quantified, as shown in the graph (c): in 8505C cells the levels of Bcl-2 decreased at all time points; in TPC1 cells there was a marked increase after 1 h and 48 h; in C643 cells the levels of Bcl-2 remain unchanged at all time points except at 24 h where there was a increase. All values presented are the mean of at least three independent experiments.

Back to article page